(Q35124726)

6 August 2017

1 reference

title

Caspofungin: first approved agent in a new class of antifungals (English)

1 reference

6 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12740003

1 January 2024

antibiotic

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12740003

1 January 2024

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.807

1 January 2024

2

John R Perfect

1 reference

6 August 2017

1

Melissa D. Johnson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12740003

1 January 2024

language of work or name

English

0 references

publication date

1 May 2003

1 reference

full work available at URL

6 August 2017

http://www.tandfonline.com/doi/pdf/10.1517/14656566.4.5.807

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.807

Expert Opinion on Pharmacotherapy

1 January 2024

published in

1 reference

6 August 2017

volume

4

1 reference

6 August 2017

issue

5

1 reference

6 August 2017

page(s)

807-823

1 reference

Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.807

Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.807

The fungal cell wall as a drug target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.807

The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.807

Cell-wall glucans of Cryptococcus neoformans Cap 67.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.807

Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.807

Comparison of caspofungin and amphotericin B for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.807

Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.807

Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.807

A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.807

In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.807

Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.807

Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.807

Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.807

Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.807

Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.807

Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.807

Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.807

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.807

In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.807

Glucan synthase complex of Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.807

The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.807

In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.807

In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.807

Efficacies of fluconazole, caspofungin, and amphotericin B in Candida glabrata-infected p47phox-/- knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.807

Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.807

Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.807

Amphotericin B-resistant Aspergillus flavus infection successfully treated with caspofungin, a novel antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.807

Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.807

Progressive cutaneous hyalohyphomycosis due to Paecilomyces lilacinus: rapid response to treatment with caspofungin and itraconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.807

Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.807

Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii

21 January 2018

3

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.807

Lipopeptide inhibitors of fungal glucan synthase

1 January 2024

5

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.807

Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872).

1 January 2024

12

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.807

Drug Metabolism and Disposition

1 January 2024

14

28

1274

BALANI SK

2000

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.807

In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)

1 January 2024

17

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.807

Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis

1 January 2024

19

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.807

Treatment of murine disseminated candidiasis with L-743,872

1 January 2024

21

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.807

Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans

1 January 2024

25

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.807

Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro

1 January 2024

26

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.807

International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group

1 January 2024

30

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.807

Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp

1 January 2024

31

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.807

Treatment of murine Candida krusei or Candida glabrata infection with L-743,872

1 January 2024

43

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.807

Treatment of histoplasmosis with MK-991 (L-743,872)

1 January 2024

45

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.807

1 January 2024

Identifiers

1 reference

6 August 2017

1 reference